Literature DB >> 17100756

Impaired interferon-gamma production in response to live bacteria and Toll-like receptor agonists in patients with ataxia telangiectasia.

J Reichenbach1, R Schubert, J Feinberg, O Beck, M Rosewich, M A Rose, S Zielen.   

Abstract

Ataxia telangiectasia (AT) is a pleiotropic autosomal recessive neurodegenerative disorder with associated immunodeficiency and cancer predisposition, caused by mutational inactivation of the ATM gene. Early death usually results from lymphoreticular malignancy or recurrent, chronic respiratory infections. Immune deficiency of AT patients is heterogeneous and involves both humoral and cellular responses. Reports on the number and integrity of immunocompetent cells in AT are conflicting. In the early phase of infection, the interleukin (IL)-12/interferon (IFN)-gamma axis plays a crucial role in first-line defence against pathogens. In a whole blood assay we studied the IL-12/IFN-gamma axis in the immune response of AT cells to the Toll-like receptor agonists lipopolysaccharide and heat-killed Staphylococcus aureus, as well as whole live M. bovis bacille Calmette-Guérin (BCG). The function of AT antigen-presenting cells was normal in terms of IL-12 production, while IFN-gamma production by T and natural killer (NK) cells was severely impaired, even in the presence of adequate co-stimulation by exogenous IL-12.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17100756      PMCID: PMC1810411          DOI: 10.1111/j.1365-2249.2006.03221.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Cutting Edge: Innate production of IFN-gamma by NK cells is independent of epigenetic modification of the IFN-gamma promoter.

Authors:  Cristina M Tato; Gislâine A Martins; Frances A High; Catherine B DiCioccio; Steven L Reiner; Christopher A Hunter
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

2.  Telomere length measurement and determination of immunosenescence-related markers (CD28, CD45RO, CD45RA, interferon-gamma and interleukin-4) in skin-homing T cells expressing the cutaneous lymphocyte antigen: indication of a non-ageing T-cell subset.

Authors:  Karsten Neuber; Saskia Schmidt; Andrea Mensch
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

3.  Relative increase of T cells expressing the gamma/delta rather than the alpha/beta receptor in ataxia-telangiectasia.

Authors:  M Carbonari; M Cherchi; R Paganelli; G Giannini; E Galli; C Gaetano; C Papetti; M Fiorilli
Journal:  N Engl J Med       Date:  1990-01-11       Impact factor: 91.245

4.  Defective interferon-gamma production in ataxia-telangiectasia.

Authors:  R Paganelli; M R Capobianchi; P M Matricardi; L Cioè; R Seminara; F Dianzani; F Aiuti
Journal:  Clin Immunol Immunopathol       Date:  1984-09

Review 5.  NK and NKT cell functions in immunosenescence.

Authors:  Eugenio Mocchegiani; Marco Malavolta
Journal:  Aging Cell       Date:  2004-08       Impact factor: 9.304

6.  Evidence that defective gamma interferon production in patients with primary immunodeficiencies is due to intrinsic incompetence of lymphocytes.

Authors:  R Paganelli; M R Capobianchi; B Ensoli; G P D'Offizi; J Facchini; F Dianzani; F Aiuti
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

Review 7.  The molecular cell biology of interferon-gamma and its receptor.

Authors:  M A Farrar; R D Schreiber
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

8.  Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2).

Authors:  Victoria Valinluck; Hsin-Hao Tsai; Daniel K Rogstad; Artur Burdzy; Adrian Bird; Lawrence C Sowers
Journal:  Nucleic Acids Res       Date:  2004-08-09       Impact factor: 16.971

9.  Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.

Authors:  William T Shearer; Howard M Rosenblatt; Rebecca S Gelman; Rebecca Oyomopito; Susan Plaeger; E Richard Stiehm; Diane W Wara; Steven D Douglas; Katherine Luzuriaga; Elizabeth J McFarland; Ram Yogev; Mobeen H Rathore; Wende Levy; Bobbie L Graham; Stephen A Spector
Journal:  J Allergy Clin Immunol       Date:  2003-11       Impact factor: 10.793

10.  Dissociated production of interleukin-2 and immune (gamma) interferon by phytohaemagglutinin stimulated lymphocytes in healthy infants.

Authors:  T Miyawaki; H Seki; K Taga; H Sato; N Taniguchi
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

View more
  7 in total

Review 1.  Natural killer cell deficiency.

Authors:  Jordan S Orange
Journal:  J Allergy Clin Immunol       Date:  2013-09       Impact factor: 10.793

2.  A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication.

Authors:  Dahlene N Fusco; Cynthia Brisac; Sinu P John; Yi-Wen Huang; Christopher R Chin; Tiao Xie; Hong Zhao; Nikolaus Jilg; Leiliang Zhang; Stephane Chevaliez; Daniel Wambua; Wenyu Lin; Lee Peng; Raymond T Chung; Abraham L Brass
Journal:  Gastroenterology       Date:  2013-02-24       Impact factor: 22.682

3.  Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging.

Authors:  Claudia E Rübe; Andreas Fricke; Thomas A Widmann; Tobias Fürst; Henning Madry; Michael Pfreundschuh; Christian Rübe
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

4.  Treatment of Granulomas in Patients With Ataxia Telangiectasia.

Authors:  Sandra Woelke; Eva Valesky; Shahrzad Bakhtiar; Helena Pommerening; L M Pfeffermann; Ralf Schubert; Stefan Zielen
Journal:  Front Immunol       Date:  2018-09-18       Impact factor: 7.561

Review 5.  Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle?

Authors:  Moussab Tatfi; Olivier Hermine; Felipe Suarez
Journal:  Front Immunol       Date:  2019-01-04       Impact factor: 7.561

6.  Altered Cerebrospinal Fluid (CSF) in Children with Ataxia Telangiectasia.

Authors:  S Woelke; R Schrewe; H Donath; M Theis; M Kieslich; R Duecker; G Auburger; R Schubert; S Zielen
Journal:  Cerebellum       Date:  2021-02       Impact factor: 3.847

7.  Simple Measurement of IgA Predicts Immunity and Mortality in Ataxia-Telangiectasia.

Authors:  Stefan Zielen; Ruth Pia Duecker; Sandra Woelke; Helena Donath; Sharhzad Bakhtiar; Aileen Buecker; Hermann Kreyenberg; Sabine Huenecke; Peter Bader; Nizar Mahlaoui; Stephan Ehl; Sabine M El-Helou; Barbara Pietrucha; Alessandro Plebani; Michiel van der Flier; Koen van Aerde; Sara S Kilic; Shereen M Reda; Larysa Kostyuchenko; Elizabeth McDermott; Nermeen Galal; Claudio Pignata; Juan Luis Santos Pérez; Hans-Juergen Laws; Tim Niehues; Necil Kutukculer; Markus G Seidel; Laura Marques; Peter Ciznar; John David M Edgar; Pere Soler-Palacín; Horst von Bernuth; Renate Krueger; Isabelle Meyts; Ulrich Baumann; Maria Kanariou; Bodo Grimbacher; Fabian Hauck; Dagmar Graf; Luis Ignacio Gonzalez Granado; Seraina Prader; Ismail Reisli; Mary Slatter; Carlos Rodríguez-Gallego; Peter D Arkwright; Claire Bethune; Elena Deripapa; Svetlana O Sharapova; Kai Lehmberg; E Graham Davies; Catharina Schuetz; Gerhard Kindle; Ralf Schubert
Journal:  J Clin Immunol       Date:  2021-09-03       Impact factor: 8.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.